Design and Implementation of a Brief, Self-Directed Course on Immunotherapy Best Practices for Neurology Trainees by Kyle M. Blackburn, Peter V. Sguigna, Lauren Tardo, Shaida Khan, Steven Vernino, Lauren Phillips

Get full text

A narrative review of neuro-ophthalmologic disease in African Americans and Hispanics with multiple sclerosis by Lauren Tardo, Amber Salter, Melanie Truong-Le, Lindsay Horton, Kyle M. Blackburn, Peter V. Sguigna

Get full text

The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives by Rehana Z Hussain, Peter V Sguigna, Annette Okai, Crystal Wright, Mariam Madinawala, Ann D Bass, Gary R Cutter, Navid Manouchehri, Olaf Stuve

Get full text

Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials by Jimin Ren, Richard B. Dewey, Austin Rynders, Jacob Evan, Jeremy Evan, Shelia Ligozio, Karen S. Ho, Peter V. Sguigna, Robert Glanzman, Michael T. Hotchkin, Richard B. Dewey, Benjamin M. Greenberg

Get full text

Cladribine tablets after treatment with natalizumab (CLADRINA) – rationale and design by Peter V. Sguigna, Rehana Z. Hussain, Annette Okai, Kyle M. Blackburn, Lauren Tardo, Mariam Madinawala, Julie Korich, Lori A. Lebson, Jeffrey Kaplan, Amber Salter, Navid Manouchehri, Olaf Stuve

Get full text

Correction: Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials by Jimin Ren, Richard B. Dewey, Austin Rynders, Jacob Evan, Jeremy Evan, Shelia Ligozio, Karen S. Ho, Peter V. Sguigna, Robert Glanzman, Michael T. Hotchkin, Richard B. Dewey, Benjamin M. Greenberg

Get full text